A Randomized, Open-Label, Two Period Crossover, Chronic Dosing, 1-Week, Pilot Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Inhalation Aerosol Administered With a Spacer Compared With Symbicort Turbuhaler in Subjects With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Low Peak Inspiratory Flow
Latest Information Update: 21 Mar 2022
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca AB
Most Recent Events
- 21 Jan 2021 Status changed from active, no longer recruiting to completed.
- 14 Dec 2020 Planned End Date changed from 4 May 2021 to 8 Feb 2021.
- 14 Dec 2020 Planned primary completion date changed from 4 May 2021 to 8 Feb 2021.